More specifically, the PIONEER program showed that oral semaglutide is efficacy and safe for adults with early T2D managed by diet and exercise, adults with advanced disease requiring daily insulin, and adults with CVD and/or CKD. The gene discussed is INS; the disease is chronic kidney disease.